HC Wainwright Issues Optimistic Forecast for ESPR Earnings

Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) - Stock analysts at HC Wainwright lifted their Q2 2025 earnings per share (EPS) estimates for shares of Esperion Therapeutics in a research note issued on Tuesday, June 17th. HC Wainwright analyst J. Pantginis now expects that the biopharmaceutical company will post earnings per share of ($0.18) for the quarter, up from their previous forecast of ($0.19). HC Wainwright currently has a "Buy" rating and a $16.00 price objective on the stock. The consensus estimate for Esperion Therapeutics' current full-year earnings is ($0.29) per share. HC Wainwright also issued estimates for Esperion Therapeutics' Q3 2025 earnings at ($0.16) EPS, Q4 2025 earnings at ($0.01) EPS and FY2025 earnings at ($0.55) EPS.

Esperion Therapeutics (NASDAQ:ESPR - Get Free Report) last announced its earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.18) by ($0.03). Esperion Therapeutics had a negative net margin of 59.03% and a negative return on equity of 0.91%. The firm had revenue of $65.00 million during the quarter, compared to analyst estimates of $54.97 million.

Other research analysts also recently issued research reports about the stock. The Goldman Sachs Group decreased their target price on shares of Esperion Therapeutics from $4.00 to $3.00 and set a "neutral" rating for the company in a research report on Thursday, April 17th. Needham & Company LLC dropped their target price on Esperion Therapeutics from $5.00 to $4.00 and set a "buy" rating on the stock in a report on Wednesday, May 7th. One analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company's stock. Based on data from MarketBeat, Esperion Therapeutics presently has an average rating of "Hold" and a consensus price target of $6.25.

Esperion Therapeutics Stock Up 0.9%

NASDAQ ESPR opened at $1.10 on Thursday. The firm's 50 day moving average is $0.96 and its 200-day moving average is $1.63. The company has a market capitalization of $218.02 million, a PE ratio of -1.37 and a beta of 0.67. Esperion Therapeutics has a 12-month low of $0.69 and a 12-month high of $3.94.

Institutional Investors Weigh In On Esperion Therapeutics

Several hedge funds have recently bought and sold shares of the company. Wasatch Advisors LP increased its position in Esperion Therapeutics by 4.9% during the fourth quarter. Wasatch Advisors LP now owns 24,482,258 shares of the biopharmaceutical company's stock worth $53,861,000 after buying an additional 1,136,245 shares during the last quarter. Two Sigma Advisers LP increased its holdings in shares of Esperion Therapeutics by 0.4% during the 4th quarter. Two Sigma Advisers LP now owns 3,616,200 shares of the biopharmaceutical company's stock worth $7,956,000 after acquiring an additional 16,100 shares during the last quarter. Nuveen Asset Management LLC raised its stake in Esperion Therapeutics by 48.6% in the 4th quarter. Nuveen Asset Management LLC now owns 3,119,253 shares of the biopharmaceutical company's stock valued at $6,862,000 after acquiring an additional 1,020,243 shares during the period. Nuveen LLC acquired a new stake in Esperion Therapeutics during the 1st quarter valued at $4,446,000. Finally, JPMorgan Chase & Co. boosted its position in Esperion Therapeutics by 18.6% during the fourth quarter. JPMorgan Chase & Co. now owns 2,454,216 shares of the biopharmaceutical company's stock worth $5,399,000 after purchasing an additional 385,099 shares during the period. 47.39% of the stock is currently owned by institutional investors and hedge funds.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.